Systemic and targeted therapy for advanced colon cancer. - Wikidata - awgldk - TriplyDB

Systemic and targeted therapy for advanced colon cancer.

Systemic and targeted therapy for advanced colon cancer.

http://www.wikidata.org/entity/Q37345922

about

Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis.Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.Implications of microRNAs in colorectal cancer development, diagnosis, prognosis, and therapeutics.Inhibition of autophagy and tumor growth in colon cancer by miR-502.Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy.Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer.Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling.Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.Biomarker-based selection of therapy for colorectal cancer.The cardiac glycoside oleandrin induces apoptosis in human colon cancer cells via the mitochondrial pathway.Recent achievements in colorectal cancer diagnostic and therapy by the use of nanoparticles.Anticancer effect of salidroside on colon cancer through inhibiting JAK2/STAT3 signaling pathway.Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer.Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here?RAC3 influences the chemoresistance of colon cancer cells through autophagy and apoptosis inhibition.Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells.Significance of PYK2 level as a prognosis predictor in patients with colon adenocarcinoma after surgical resection

P2860

Q33961980-BCF6A614-713B-4A83-AAD5-E48D23164428 Q34621867-96149D5E-BAD4-4722-A0B1-CBD8C1E2BDF8 Q34693160-6246EA71-B627-4243-99F7-A3389ABA4A1D Q35556903-3E61A596-ECFD-4671-8004-067BE3DBF285 Q35565247-0441CBBD-4507-46BB-BE25-C1D9CEBA9D59 Q36173829-884562D2-89FD-4C99-A159-40130C90FE8D Q36260634-AE3E9A50-6B18-4FD3-A021-A05647374B45 Q36742896-17438C3B-9154-4C7A-BAF7-D704A5EB1E20 Q37268127-9FDFE61A-A203-4248-A3F2-5E8CBBD6319B Q37448192-DDB03D96-9601-4A61-BDEB-41D1B015BCE8 Q37520284-C00168D3-E3C5-4DF7-B184-43C01F6D2B9C Q37718417-F4D42FD6-3299-4232-847E-69F539258D1B Q37886995-E10C8271-57B4-46D9-9B5F-ABF7C13562EE Q38700786-B432B73E-710F-4D71-951C-EB19A1354F2C Q38717321-5C956B67-0786-41B8-B37A-53024AE304F5 Q38901701-8EDE525B-47A9-44E9-A9CE-7688D98C2117 Q39496459-7B25BAE7-1ECF-42C9-B3DC-2D04DDBE2F4B Q39608346-A1E4A054-78EE-49D1-9117-142546322642 Q43191951-193DD17B-7C52-4F87-A081-24A3FB7F48AD Q47101055-0779C07A-E0CB-483A-9C50-3B37EDD7147E Q54430665-C7167344-9351-4D99-BCBB-198EA448EE90 Q59125967-23EBF12C-AE60-475D-A62A-CF86F000317C

P2860

Systemic and targeted therapy for advanced colon cancer.

http://www.wikidata.org/entity/Q37345922

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Systemic and targeted therapy for advanced colon cancer.

@en

Systemic and targeted therapy for advanced colon cancer.

@nl

type

label

Systemic and targeted therapy for advanced colon cancer.

@en

Systemic and targeted therapy for advanced colon cancer.

@nl

prefLabel

Systemic and targeted therapy for advanced colon cancer.

@en

Systemic and targeted therapy for advanced colon cancer.

@nl

P1433

Q37345922-A6287443-9268-4DD7-A0D4-B49C80E354E9

P1476

Q37345922-3D809B55-6DB1-4757-9382-82E3084719F5

P2093

Q37345922-6BA5BF4A-15D9-460F-8D95-AB07C639CD1B

Q37345922-90D5DA15-4EC5-4218-9291-49718D8E3B18

Q37345922-A1262F0D-88BF-4FA8-8575-533A4BD53824

P2860

Q37345922-07D4D69B-27C3-4AD3-8DBC-EF22EDDBBD5C

Q37345922-0B67F2D5-D066-4C33-A5F9-A1586D9DF8F0

Q37345922-0D1CC2F5-8E2E-4735-A7A8-8AA88C47BA28

Q37345922-13B8E87D-FC93-4948-AA34-0E81EDCA2517

Q37345922-15F1DC54-3DB4-499E-8CA6-CBD4F5EF0ABB

Q37345922-18EE4370-5052-4FFA-97F8-836915D243C3

Q37345922-1E0A637F-10CE-41BF-BDE2-888F8D0E354E

Q37345922-1FB0F3D7-76A8-4520-9E04-3B23738B4808

Q37345922-20B243A9-D80C-401B-9E54-C9A7D54FDB5D

Q37345922-21CC3376-6913-4692-BE77-9325DDFFDF20

P304

Q37345922-33BB9B9A-F6DA-43AD-9D8E-DC51E8C44B1D

P31

Q37345922-86A265A0-CDE9-4E78-A62D-EEC9E6EC45C7

P356

Q37345922-E151DF23-CC31-4D32-BC0B-2413D23994CE

P433

Q37345922-B6E6D53F-3DCE-472F-AD08-D2F815A75065

P478

Q37345922-160D2ACE-A6D9-40FF-9B57-D5FBF2F27D91

P577

Q37345922-434406D0-2D29-43A6-9845-6AF3B7FEA9F0

P698

Q37345922-D98DBD01-0357-419C-86E0-9FFF542E24ED

P356

17474124.2.1.135

P1433

Expert Review of Gastroenterology & Hepatology

P1476

Systemic and targeted therapy for advanced colon cancer.

@en

P2093

John P Lynch

http://www.w3.org/2001/XMLSchema#string

Sanjay R Hegde

http://www.w3.org/2001/XMLSchema#string

Weijing Sun

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor

P304

135-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474124.2.1.135

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19072376

http://www.w3.org/2001/XMLSchema#string